Radius Health (RDUS) Receives Analyst Rating

Radius Health (RDUS) : The consensus on Radius Health (RDUS) based on 6 analyst recommendation on the company stock is 1.67, which is interpreted as a Buy recommendation. Zacks Investment Research has issued a rank of 4 which endorses a Sell on the stock. However, 4 brokers have a differing view as they consider the stock to be a Strong Buy at current levels. 2 experts consider that the stocks earnings and the quoted price is in harmony, hence, they give it a Hold rating.

Radius Health (RDUS) : The highest short term price target forecast on Radius Health (RDUS) is $70 and the lowest target price is $24. A total of 5 equity analysts are currently covering the company. The average price of all the analysts is $52.2 with a standard deviation of $18.36.


Radius Health (NASDAQ:RDUS): After opening at $54.51, the stock dipped to an intraday low of $53.08 on Thursday. However, the bulls stepped in to buy at lower levels and pushed the stock higher. The stock touched an intraday high of $54.74 and the buying power remained strong till the end. The stock closed at $54.49 for the day, a gain of 0.15% for the day session. The total traded volume was 640,141. The stocks close on the previous trading day was $54.41.

Radius Health, Inc. is a science-driven biopharmaceutical company focused on developing therapeutics for patients with osteoporosis, as well as other serious endocrine-mediated diseases. The Companys lead product candidate is abaloparatide (BA058), a bone anabolic for use in the reduction of fractures in postmenopausal osteoporosis delivered through subcutaneous injection, which it refers to as abaloparatide-SC and is in Phase III development. The Company is leveraging its investment in Abaloparatide-SC to develop a line extension that is designed to improve patient convenience by enabling administration of abaloparatide through an investigational short-wear-time patch, which the Company refers to as abaloparatide-TD. The Companys clinical product portfolio also includes the investigational drug RAD1901, a selective estrogen receptor down regulator/degrader (SERD) and RAD140, a nonsteroidal selective androgen receptor modulator (SARM), for the treatment of breast cancer.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.